Guest Editorial
The Trans-Pacific Partnership Agreement: a threat to affordable medicines and public health PhRMA has long criticized medicines insurance schemes premised on cost-effectiveness and reference pricing such as the Pharmaceutical Benefits Scheme (PBS) in Australia and PHARMAC in New Zealand. The PhRMA submission to the USTR on the TTPA specifically targets alleged 'market access barriers… inadequate consultative mechanisms and transparency concerns in countries like New Zealand' 6 . But the governments of Australia and New Zealand are unlikely to accept the whole-sale winding-back of the PBS and PHARMAC. The Australian government affirms that it 'has not and will not accept provisions that limit its capacity to put health warnings or plain packaging requirements on tobacco products or its ability to continue the Pharmaceutical Benefits Scheme' 7 . But US pressures may well result in incremental policy adjustments which weaken cost-effectiveness assessments and reference pricing. The largest generics supplier to the PBS, Alphapharm (a subsidiary of the global generics firm Mylan), is 'deeply concerned about the impact that the [TPPA] could have on the generic pharmaceutical industry in Australia, on consumers and on the Government's budget' 8 
.
Of particular concern is the potential impact of the TPPA on access to affordable medicines in developing countries. Prices on first generation HIV drugs have come down radically in the past decade through generics competition, notably through the entry of Indian suppliers such as CIPLA. International programs to treat HIV/AIDS depend on access to affordable quality generic drugs. Leaked documents reveal clearly that the USTR is pursuing aggressive TRIPS-Plus measures, categorises by the Médecins Sans Frontières as follows 9 :
a. The USTR is seeking to broaden the scope of patentability to facilitate patenting of new forms of old medicines that offer no added therapeutic efficacy. Governments should no longer be able to define key terms such as 'novelty', 'inventive step' and 'industrial applicably' in a way that reflects national priorities. In India this conflict is focused on paragraph 3(d) in the Indian Patent Act which prevents 'evergreening' by accepting patents on known substances only for therapeutically effective modifications. . The 2001 WTO Doha 'Declaration on the TRIPS Agreement and Public Health' was a response to the global mobilisation for public health and justice. The Declaration affirmed that TRIPS 'can and should be interpreted and implemented in a manner supportive of WTO members' right to protect public health and, in particular, to promote access to medicines for all' 2 .
The United States since 2001 has sought to undermine the letter and spirit of the Declaration on TRIPS and Public Health through 'TRIPS-plus' provisions in bilateral and regional 'free trade' agreements 3, 4 . One such regional initiative is the TransPacific Partnership Agreement (TPPA) being negotiated between Singapore, New Zealand, Chile, Brunei, the United States, Australia, Peru, Vietnam and Malaysia. Other countries such as Japan, South Korea, and India are likely to join the process. The TPPA is not limited to 'trade' but potentially impacts on the capacity of national governments to implement domestic policy in a range of areas including environmental protection, the regulation of tobacco and alcohol, and health more broadly.
A leaked draft of the negotiating position of the United States Trade Representative (USTR) reveal demands for IPR protection that go well beyond the requirements of TRIPS 5 . The USTR is linked closely to business groups such as the Pharmaceutical Research and Manufacturers of America (PhRMA) which represents 'big pharma'. The determined objective of PhRMA and the USTR is to obstruct and delay as far as possible price competition resulting from the entry of cheaper generic brands. It is a depressing irony that monopoly privileges, granted by governments -patents and other forms of 'intellectual property' -which impede competition, are pursued in the name of 'free trade'.
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Pre-grant opposition allows third parties, including NGOs, public health groups, and competing firms, to challenge a patent application as unmerited, thus expediting generic competition. 
